|
1
|
Morrison DK: The Raf-1 kinase as a
transducer of mitogenic signals. Cancer Cells. 2:377–382.
1990.PubMed/NCBI
|
|
2
|
Rapp UR: Role of Raf-1 serine/threonine
protein kinase in growth factor signal transduction. Oncogene.
6:495–500. 1991.PubMed/NCBI
|
|
3
|
Moodie SA, Willumsen BM, Weber MJ and
Wolfman A: Complexes of Ras-GTP with Raf-1 and mitogen-activated
protein kinase. Science. 260:1658–1661. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morrison DK and Cutler RE: The complexity
of Raf-1 regulation. Curr Opin Cell Biol. 9:174–179. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vojtek AB, Hollenbeg SM and Cooper JA:
Mammalian ras interacts directly with the serine/threonine kinase
Raf. Cell. 74:205–214. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zimmermann S and Moelling K:
Phosphorylation and regulation of Raf by Akt (protein kinase B).
Science. 286:1741–1744. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stanton VJ, Nichols DW, Laudano AP and
Cooper GM: Definition of the human raf amino-terminal regulatory
region by deletion mutagenesis. Mol Cell Biol. 9:639–647.
1989.PubMed/NCBI
|
|
8
|
Dent P, Haser W, Haystead TAJ, Vincent LA,
Roberts TM and Sturgill TW: Activation of mitogen-activated protein
kinase kinase by v-Raf in NIH3T3 cells and in vitro. Science.
257:1404–1407. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cleveland JL, Troppmair J, Packham G,
Askew DS, Lloyd P, Gonzalez-Garcia M, Nunez H, Ihle JN and Rapp UR:
v-raf suppresses apoptosis and promotes growth of
interleukin-3-dependent myeloid cells. Oncogene. 9:2227–2233.
1994.PubMed/NCBI
|
|
10
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes
J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S,
Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley
J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G,
Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson
A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL,
Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and
Futreal PA: Mutation of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ciampi R, Knauf JA, Kerler R, Gandhi M,
Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE:
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway
activation in thyroid cancer. J Clin Invest. 115:94–101. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wan PTC, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D and Marais R: Mechanism of activation of the RAF-ERK
signaling pathway by oncogenic mutation of B-RAF. Cell.
116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okuda K, D’Andrea A, Van Etten RA and
Griffin JD: A chimeric receptor/oncogene that can be regulated by a
ligand in vitro and in vivo. J Clin Invest. 100:1708–1715. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sternberg PW and Alberola-Ila J:
Conspiracy theory: Ras and Raf do not act alone. Cell. 95:447–450.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
D’Andrea AD, Yoshimura A, Youssoufian H,
Son LI, Koo JW and Lodish HF: The cytoplasmic region of the
erythropoietin receptor contains non-overlapping positive and
negative growth-regulatory domains. Mol Cell Biol. 11:1980–1987.
1991.
|
|
16
|
Barber DE, DeMartino JC, Showers MO and
D’Andrea AD: A dominant negative erythropoietin (EPO) receptor
inhibits EPO-dependent growth and blocks F-gp55-dependent
transformation. Mol Cell Biol. 14:2257–2265. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Samuels ML, Weber MJ, Bishop JM and
McMahon M: Conditional transformation of cells and rapid activation
of the mitogen-activated protein kinase cascade by an
estradiol-dependent human Raf-1 protein kinase. Mol Cell Biol.
13:6241–6252. 1993.
|
|
18
|
Farrar MA, Alberola-Ila J and Perlmutter
RM: Activation of the raf-1 kinase cascade by coumermycin-induced
dimerization. Nature. 383:178–181. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leevers SJ, Paterson HF and Marshall CJ:
Requirement for Ras in Raf activation is overcome by targeting Raf
to the plasma membrane. Nature. 369:411–414. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y,
Shujath J, Gawlak S, Eveleigh D, Rowley B, Leu L, Adnane L, Lynch
M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE,
Bollag G and Trail PA: BAY 43-9006 exhibits broad spectrum oral
antitumor activity and targets the RAF/MEK/ERK pathway and receptor
tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
